Hip Fractures Clinical Trial
— RESTOREOfficial title:
A Phase-4, Multicenter, Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of EXPAREL When Administered Via Fascia Iliaca Compartment Block Versus Fascia Iliaca Compartment Block With Continuous Infusion of Ropivacaine Per Standard of Care Through a Catheter in Intertrochanteric Hip Fracture Patients
NCT number | NCT03955458 |
Other study ID # | 402-C-415 |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | August 26, 2019 |
Est. completion date | May 2020 |
Verified date | February 2020 |
Source | Pacira Pharmaceuticals, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the effect of EXPAREL on total opioid consumption through 72 hours following fascia iliaca compartment block (FICB) in subjects undergoing repair of intertrochanteric hip fracture.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 2020 |
Est. primary completion date | May 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years to 85 Years |
Eligibility |
Inclusion Criteria: 1. Individuals between 65 and 85 years of age (inclusive of) at screening. 2. Intertrochanteric femoral fractures with American Society of Anesthesiology physical status 1, 2, or 3. 3. Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments. Exclusion Criteria: 1. Hip fracture that requires total arthroplasty. 2. Patients transferred from other hospitals. 3. Patients that have other acute fractures. 4. Pre-existing dementia (Mini-Mental State examination score <20) or delirium (Mini-Mental State examination score <24). 5. Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications for which an alternative is not named in the protocol (e.g., amide-type local anesthetics, opioids, bupivacaine, ropivacaine, acetaminophen, NSAIDs). 6. Serious systemic comorbidities that cause a contraindication for EXPAREL/bupivacaine (severe hepatic or renal impairment) or ropivacaine. 7. Use of anticoagulants (including aspirin, except low dose aspirin). 8. Chronic opioid use of = 20 morphine milligram equivalent (MME)/day for more than 7 days in the last 30 days. 9. Body Mass Index (BMI) <17 kg/m2 or >45 kg/m2. 10. Known history of renal or hepatic dysfunction, coagulation or bleeding disorder. 11. Concurrent painful physical condition that may require analgesic treatment (such as long-term, consistent use of opioids) in the post-operative period for pain that is not strictly related to the surgery and which may confound the post-operative assessments based on the physician's discretion. 12. Clinically significant medical disease that, in the opinion of the investigator, would make participation in a clinical study inappropriate. This includes any psychiatric or other conditions that would constitute a contraindication to participation in the study. 13. History of suspected or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years. 14. Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study. 15. Previous participation in an EXPAREL study. 16. Resident of a skilled nursing facility (SNF), long-term acute care (LTAC) facility, inpatient rehabilitation facility (IRF), or nursing home. Participants from assisted living facilities will be eligible for the study. In addition, the subject may be withdrawn from the study if the subject meets the following criteria during the hospital stay: 17. Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that might render the subject medically unstable or complicate the subject's post-operative course. 18. Subjects who undergo hip fracture surgery more than 30 hours after admission to the Emergency Department. |
Country | Name | City | State |
---|---|---|---|
United States | Cleveland Clinic | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
Pacira Pharmaceuticals, Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary objective (total opioid consumption in morphine equivalents) | to compare total opioid consumption in morphine equivalents following FICB with EXPAREL +bupivacaine HCl to that following continuous infusion of ropivacaine via catheter, from end of FICB placement through 72 hours post-FICB, in subjects undergoing repair of intertrochanteric hip fracture To be measured as date, time, and dosage of all medication administered from the time ICF is signed to 72-hours post-surgery. | Through 72 hours post-FICB |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02507609 -
Deep Neuromuscular Block on Cytokines Release and Postoperative Delirium
|
N/A | |
Completed |
NCT03906864 -
Care Pathway for Sub-acute Hip Rehabilitation
|
N/A | |
Recruiting |
NCT04063891 -
Vibration Therapy as an Intervention for Enhancing Trochanteric Hip Fracture Healing in Elderly Patients
|
N/A | |
Completed |
NCT05039879 -
Life Improving Factors After a Hip Fracture
|
||
Not yet recruiting |
NCT03887494 -
Study of the Impact of the Femoral Implant "Y-strut" on Lytic Bone Metastases of the Femoral Neck (WAZA-ARY)
|
N/A | |
Terminated |
NCT03065101 -
Trigen InterTAN vs Sliding Hip Screw RCT
|
N/A | |
Completed |
NCT03695081 -
Patient Pathway Pharmacist - Optimal Drug-related Care
|
N/A | |
Completed |
NCT03545347 -
Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture.
|
Phase 2 | |
Recruiting |
NCT05971173 -
Nutritional Optimization and Bone Health Management for Older Adults Undergoing Hip Fracture Surgery
|
Early Phase 1 | |
Active, not recruiting |
NCT04957251 -
Anterior vs Posterior Approach for Hip Hemiarthroplasty
|
N/A | |
Terminated |
NCT04372966 -
Uncemented Versus Cemented Total Hip Arthroplasty for Displaced Intracapsular Hip Fractures
|
N/A | |
Withdrawn |
NCT05030688 -
Fascia Iliaca Compartment Block and PENG Block for Hip Arthroplasty
|
N/A | |
Completed |
NCT04424186 -
'Rehabilitation for Life'
|
N/A | |
Not yet recruiting |
NCT04183075 -
Impact of a Nutritional Supplement on the Recovery of the Nutritional Status of Patients With Spontaneous Hip Fracture
|
N/A | |
Withdrawn |
NCT05518279 -
Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures
|
Phase 3 | |
Not yet recruiting |
NCT02892968 -
ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients
|
N/A | |
Not yet recruiting |
NCT02223572 -
Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture
|
N/A | |
Active, not recruiting |
NCT02247791 -
Uncemented Compared to Cemented Femoral Stems in Total Hip Arthroplasty
|
N/A | |
Completed |
NCT00746876 -
Unipolar or Bipolar Hemiarthroplasty in the Treatment of Displaced Femoral Neck Fractures.
|
N/A | |
Completed |
NCT00058864 -
The HIP Impact Protection Program (HIP PRO)
|
N/A |